Ocular Therapeutix, Inc. (NASDAQ:OCUL) to Post Q2 2023 Earnings of ($0.30) Per Share, HC Wainwright Forecasts

Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Rating) – HC Wainwright reduced their Q2 2023 earnings estimates for shares of Ocular Therapeutix in a research note issued on Tuesday, May 9th. HC Wainwright analyst Y. Chen now anticipates that the biopharmaceutical company will earn ($0.30) per share for the quarter, down from their prior forecast of […]

Related Keywords

Amarpreets Sawhney ,Robertw Baird , ,Geode Capital Management ,Ocular Therapeutix Inc ,Nasdaq ,Deltec Asset Management ,Vanguard Group Inc ,Ocular Therapeutix Company Profile ,Ocular Therapeutix ,Get Rating ,Therapeutix Stock Down ,Asset Management ,Capital Management ,Endurant Capital Management ,Farhad Khosravi ,Ocular Therapeutix Daily ,Nasdaq Ocul ,Hocul ,Medical ,Earnings Estimates ,Hc Wainwright ,